Latest News
Conference Coverage
Signals of gut microbiome interaction with experimental Alzheimer’s drug prompt new trial
LOS ANGELES – The first reporting of microbiome data in an Alzheimer’s drug trial opens the door for further investigation of this new endpoint....
From the Journals
Lancet joins movement to reject ‘manels’
The Lancet Group also issued a diversity pledge, aiming to include more women, people of color, and colleagues from lower- and middle-income...
From the Journals
Sleep disorder treatment tied to lower suicide attempt risk in veterans
Previous research has explored the link between sleep disturbances and suicide attempts, but less has been done to look at specific sleep problems...
Latest News
Medical societies urge action to reduce gun violence
Comprehensive criminal background checks for all firearm purchases, freedom to counsel patients are key asks.
Feature
Sleep aids and dementia: Studies find both risks and benefits
LOS ANGELES – Researchers found differences in dementia risk by race and sex; a possible mechanism of damage from certain sleep-promoting...
Literature Review
Vaccination is not associated with increased risk of MS
Data indicate an association between vaccination and lower likelihood of incident MS, but do not support conclusions about whether vaccination has...
Conference Coverage
Benzodiazepines, hypnotics don’t increase Alzheimer’s pathology
LOS ANGELES – The drugs were not associated with Alzheimer’s pathology, but were associated with a trend toward greater loss of neurons in the...
From the Journals
Researchers examine potential causes of dementia in CTE
More years of football play were associated with white matter changes and tau accumulation, which were associated with increased risk of dementia...
Feature
The states of health care: Ranking the best and worst
Minnesota has more than 10,000 lakes to brag about, the results of a WalletHub analysis suggest.
Feature
Burnout gets personal for 68% of physicians
Young primary care providers beware.
Conference Coverage
Efficacy of erenumab is sustained over more than 4 years of treatment
PHILADELPHIA – Among patients with episodic migraine, 4.5 years of preventive treatment with erenumab is effective, safe, and well tolerated,...